BXPHF Company Profile and Key Details

Average 10-day trading volume of 26.20 thousand shares is below the 3-month average of 60.70 thousand, indicating normal recent market interest.

Botanix Pharmaceuticals Limited earnings surprise history is a mixed track record. The quarter that ended February 26, 2026, missed forecasts by 69.12%. The prior quarter beat by 195.14%. Over the last six quarters, Apple has recorded several small beats. These include -1796.77% in February 26, 2025.

Botanix Pharmaceuticals Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.01. This means the shares are trading above this model’s fair value.

The stock is currently mid-range between its 52-week high and low $0.01 and $0.13. With a market capitalization of about $45.94 million, Botanix Pharmaceuticals Limited is classified as a micro-cap and shows market-like volatility (beta ~0.86). Key stats such as the average daily volume over the past year has been around 14.88 thousand shares, trading with heavier-than-usual volume. Headquartered in West Perth, WA, Botanix Pharmaceuticals Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Howie McKibbon, the company employs approximately 11 people and listed since September 09, 2019. Botanix Pharmaceuticals Ltd is a dermatology company that focuses on developing safe and effective topical treatments for serious skin conditions.

Our AI price prediction model suggests that Botanix Pharmaceuticals Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows Botanix Pharmaceuticals Limited trading at a premium to the broader market with a P/E of -0.51.

Botanix Pharmaceuticals Limited trades at a P/E ratio of -0.51, slightly below the S&P 500 average, with a price-to-sales ratio of 2.95 and a price-to-book ratio of 0.86 suggesting the stock is closer to book value. The P/FCF stands at -0.8, also below market averages.